Shares of ShockWave Medical SWAV were flat in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 17.39% year over year to ($0.38), which beat the estimate of ($0.55).
Revenue of $19,590,000 higher by 72.86% from the same period last year, which beat the estimate of $14,690,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
ShockWave Medical hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Nov 09, 2020
Time: 04:30 PM
ET Webcast URL: https://ir.shockwavemedical.com/events/event-details/shockwave-medical-inc-q3-2020-earnings-conference-call
Recent Stock Performance
Company's 52-week high was at $79.74
52-week low: $22.01
Price action over last quarter: Up 56.79%
Company Profile
ShockWave Medical Inc a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.